Animace načítání

Stránka se připravuje...


Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

XXŘ&Xxxxxx;XXX&Xxxxxx; XXXXXX (EU) 2015/1221

xx dne 24. čxxxxxxx 2015,

kterým se xxx &xxxxxx;čxxx xřxxxůxxxxx&xxxxxx; xěxxxxxxxxxxxxx&xxxxxx;xx pokroku xěx&xxxxxx; xxř&xxxxxx;xxx&xxxxxx; Evropského xxxxxxxxxx x&xxxx;Xxxx (XX) č.&xxxx;1272/2008 x&xxxx;xxxxxxxxxxx, označování a balení x&xxxxxx;xxx x&xxxx;xxěx&xxxxxx;

(Text s x&xxxxxx;xxxxxx xxx EHP)

XXXXXXX&Xxxxxx; XXXXXX,

x&xxxx;xxxxxxx xx Smlouvu x&xxxx;xxxxxx&xxxxxx;x&xxxxxx; Xxxxxxx&xxxxxx; xxxx,

x&xxxx;xxxxxxx xx xxř&xxxxxx;xxx&xxxxxx; Evropského xxxxxxxxxx x&xxxx;Xxxx (XX) č.&xxxx;1272/2008 xx dne 16. xxxxxxxx 2008 x&xxxx;xxxxxxxxxxx, označování a balení x&xxxxxx;xxx x&xxxx;xxěx&xxxxxx;, o změně x&xxxx;xxx&xxxxxx;xx&xxxxxx; xxěxxxx 67/548/XXX x&xxxx;1999/45/XX x&xxxx;x&xxxx;xxěxě nařízení (XX) č.&xxxx;1907/2006 (1), x&xxxx;xxxx&xxxxxx;xx xx čx.&xxxx;37 xxxx.&xxxx;5 xxxxxx&xxxxxx;xx xxř&xxxxxx;xxx&xxxxxx;,

xxxxxxxx x&xxxx;xěxxx xůxxxůx:

(1)

Č&xxxxxx;xx 3 přílohy XX xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008 xxxxxxxx xxx xxxxxxx harmonizovaných xxxxxxxxxx&xxxxxx; x&xxxx;xxxxčxx&xxxxxx; nebezpečných x&xxxxxx;xxx. X&xxxx;xxxxxxx 3.1 xx xxxxxx xxxxxx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; a označení xxxxxxxčx&xxxxxx;xx x&xxxxxx;xxx na x&xxxxxx;xxxxě xxxx&xxxxxx;xx&xxxxxx; xxxxxxxx&xxxxxx;xx x&xxxx;č&xxxxxx;xxxxx 2 až 5 xř&xxxxxx;xxxx X&xxxx;xxř&xxxxxx;xxx&xxxxxx; (ES) č.&xxxx;1272/2008. V tabulce 3.2 xx uveden xxxxxx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; x&xxxx;xxxxčxx&xxxxxx; xxxxxxxčx&xxxxxx;xx x&xxxxxx;xxx xx x&xxxxxx;xxxxě xxxx&xxxxxx;xx&xxxxxx; xxxxxxxx&xxxxxx;xx x&xxxx;xř&xxxxxx;xxxx XX xxěxxxxx Xxxx 67/548/XXX (2).

(2)

Xxxxxxx&xxxxxx; xxxxxxřx xxx xxxxxxx&xxxxxx; x&xxxxxx;xxx (XXXX) byly x&xxxx;xxxxxxx x&xxxx;čx&xxxxxx;xxxx&xxxx;37 xxř&xxxxxx;xxx&xxxxxx; (ES) č.&xxxx;1272/2008 předloženy x&xxxxxx;xxxx xx nové xxxx xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxxx&xxxxxx; klasifikace x&xxxx;xxxxčxx&xxxxxx; xěxxxx&xxxxxx;xx látek. Xx základě stanovisek x&xxxx;xěxxx x&xxxxxx;xxxůx, xxxx&xxxxxx; xxxxx X&xxxxxx;xxx xxx xxxxxxx&xxxxxx;x&xxxxxx; xxxxx (XXX) xůxxx&xxxxxx;x&xxxxxx; x&xxxx;x&xxxxxx;xxx Xxxxxxx&xxxxxx; xxxxxxxx xxx chemické x&xxxxxx;xxx, xxxxž i připomínek x&xxxxxx;čxxxxěx&xxxxxx;xx xxxxx, xx xxxxx&xxxxxx; xxěxxx xř&xxxxxx;xxxx XX uvedeného nařízení xxx&xxxxxx;xx čx xxxxxxxxxxxx xxxxxxxxxxxx&xxxxxx; klasifikace x&xxxx;xxxxčxx&xxxxxx; xěxxxx&xxxxxx;xx látek.

(3)

Pokud xxx x&xxxx;x&xxxxxx;xxx &xxxxx;xxxxxxxx xxxxčx&xxxxxx; &xxxxxx; %&xxxxx; (č.&xxxx;XX: 231-714-2), xxxx xxx&xxxxxx; x&xxxx;xxxxxxxxx xxx&xxxxxx; xěxxxx&xxxxxx; &xxxxxx;xxxx pro xř&xxxxxx;xx xxxxxxxčxxxxx &xxxxx;xxxxx&xxxxxx; xxxxxxxx&xxxxx;, xxxx&xxxxxx; naznačují, žx xxxxxxxxxxx xxx tuto xř&xxxxxx;xx xxxxxxxčxxxxx xxxxxxčxxxx&xxxxxx; xx xxxxxxxxxx výboru XXX, xxž xx xxxx&xxxxxx;x&xxxxxx; na xxxx&xxxxxx;&xxxxxx;xx &xxxxxx;xxx&xxxxxx;xx, xx nemusela x&xxxxxx;x přiměřená. Xxxx xř&xxxxxx;xx nebezpečnosti xx xxxxx neměla x&xxxxxx;x xxřxxxxx xx přílohy XX xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008, xxxxx výbor XXX xxxxx&xxxxxx; xxxxxxxxxx x&xxxx;xxx&xxxxxx;x xxxxxxxx&xxxxxx;x, xxx&xxxxxx;xxx x&xxxxxx;xxxxx xxxxxx&xxxxxx; xř&xxxxxx;xx xxxxxxxčxxxxx xxxxžxx&xxxxxx; v dosavadním xxxxxxxxxx x&xxxxxx;xxxx RAC xx xxřxxxxx být xěxx.

(4)

Xxxxx xxx x&xxxx;x&xxxxxx;xxx &xxxxx;xxxxx, dodecyl-, rozvětvený“ (č.&xxxx;XX: 310-154-3), výbor XXX xxxxxxxx&xxxxxx;x&xxxxxx; xxx&xxxxxx; xxxxxxxxxx ohledně xxxxxxxxx&xxxxxx;xx xxxxxxxxxčx&xxxxxx;xx xxxxxů, které xx xxxžxx&xxxxxx; xxx xř&xxxxxx;xx xxxxxxxčxxxxx „toxický xxx reprodukci“. Xxxx xř&xxxxxx;xx nebezpečnosti xx xxxxx neměla být xxřxxxxx xx xř&xxxxxx;xxxx XX xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008, xxxxx xxxx xxxxxxxxxx nebude xxxxxčxxx.

(5)

Xxxxžxx&xxxxxx;x&xxxxxx; xxx&xxxxxx;xx xxxxxxxxxxxx&xxxxxx;xx klasifikací xx xxxěxx být xxžxxxx&xxxxxx;xx xxxxx, xxxxxxž xxxxxxxxx&xxxxxx; xxxxx xxxřxxxxxx xxčxx&xxxxxx; časové xxxxx&xxxxxx; xx xx, aby xřxxxůxxxxxx označování x&xxxx;xxxxx&xxxxxx; x&xxxxxx;xxx x&xxxx;xxěx&xxxxxx; xxx&xxxxxx;x xxxxxxxxxx&xxxxxx;x x&xxxx;xxxxxxx stávající x&xxxxxx;xxxx. Xxxxě xxxx xxxxx xxxřxxxxxx určité čxxxx&xxxxxx; xxxxx&xxxxxx; x&xxxx;xx xx, xxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxxx&xxxxxx; xxxx&xxxxxx;xxx&xxxxxx; x&xxxx;xxx&xxxxxx;xx xxxxxxxxxxxx&xxxxxx;xx xxxxxxxxxx&xxxxxx; x&xxxxxx;xxx xxxxxxxxxxxx&xxxxxx;xx jako xxxxxxxxxxx&xxxxxx;, xxxxxxxx&xxxxxx; xxxx toxické xxx reprodukci, xxxxxxxx&xxxxxx; 1&xxxx;X x&xxxx;1X (xxxxxxx 3.1) x&xxxx;xxxxxxxx&xxxxxx; 1 x&xxxx;2 (xxxxxxx&xxxx;3.2) xxxx xxxx xxxxxx xxxxxx&xxxxxx; xxx xxxx&xxxxxx; xxxxxxxxx x&xxxx;xxžxxxx&xxxxxx; xxxxxxx dlouhodobé xxxř&xxxxxx;xxxx&xxxxxx; účinky xx xxxx&xxxxxx;x xxxxxřxx&xxxxxx;, xxxx&xxxxxx;xx xxx povinnosti xxxxxxxx&xxxxxx; x&xxxx;čx&xxxxxx;xxx&xxxx;23 xxř&xxxxxx;xxx&xxxxxx; Xxxxxxx&xxxxxx;xx xxxxxxxxxx a Rady (XX) č.&xxxx;1907/2006 (3).

(6)

X&xxxx;xxxxxxx x&xxxx;xřxxxxxx&xxxxxx;xx ustanoveními xxř&xxxxxx;xxx&xxxxxx; (XX) č. 1272/2008, xxxx&xxxxxx; xxxžňxx&xxxxxx; dobrovolně xxxž&xxxxxx;x xxx&xxxxxx; xxxxxxxxx&xxxxxx; xř&xxxxxx;xx, by dodavatelé xěxx mít xxžxxxx xxxž&xxxxxx;x nové xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx x&xxxx;xxxxx&xxxxxx;xxx&xxxxxx;x&xxxxxx;x způsobem xxxxxxxxxě xřxxxůxxxxx xxxxčxx&xxxxxx;x&xxxxxx; x&xxxx;xxxxx&xxxxxx; před xxůxxx x&xxxx;xxxxžxx&xxxxxx; xxxxxxx.

(7)

Xxxxřxx&xxxxxx; stanovená x&xxxxxx;xxx xxř&xxxxxx;xxx&xxxxxx;x xxxx x&xxxx;xxxxxxx xx stanoviskem x&xxxxxx;xxxx xř&xxxxxx;xxx&xxxxxx;xx podle čx&xxxxxx;xxx&xxxx;133 nařízení (ES) č.&xxxx;1907/2006,

XŘXXXXX XXXX XXŘ&Xxxxxx;XXX&Xxxxxx;:

Čx&xxxxxx;xxx&xxxx;1

Xř&xxxxxx;xxxx XX xxř&xxxxxx;xxx&xxxxxx; (XX) č.&xxxx;1272/2008 xx xěx&xxxxxx; x&xxxx;xxxxxxx x&xxxx;xř&xxxxxx;xxxxx xxxxxx nařízení.

Čx&xxxxxx;xxx&xxxx;2

Xxxxxxxě od čl. 3 xxxx.&xxxx;2 lze xxxxxxxxxxxx&xxxxxx; xxxxxxxxxxx xxxxxxxx&xxxxxx; x&xxxx;xř&xxxxxx;xxxx xxxxxx xxř&xxxxxx;xxx&xxxxxx; xxxž&xxxxxx;x xřxx xxxxx xxxxxx&xxxxxx;x x&xxxx;čx.&xxxx;3 xxxx.&xxxx;2.

Čx&xxxxxx;xxx&xxxx;3

1.&xxxx;&xxxx;&xxxx;Xxxx nařízení xxxxxxxx x&xxxx;xxxxxxxx xxxx&xxxxxx;x&xxxxxx;x xxxx xx xxxx&xxxxxx;&xxxxxx;xx&xxxxxx; v Úředním xěxxx&xxxxxx;xx Xxxxxxx&xxxxxx; xxxx.

2.   Článek 1 se pro x&xxxxxx;xxx x&xxxx;xxěxx xxxžxxx xxx xxx 1. xxxxx 2017.

Toto xxxxxxxx xx xxxxxxx x&xxxx;xxxxx rozsahu x&xxxx;xxxxx xxxxxxxxxx ve xxxxx xxxxxxxxx státech.

V Bruselu xxx 24. xxxxxxxx 2015.

Xx Xxxxxx

xxxxxxxx

Xxxx-Xxxxxx XXXXXXX


(1)&xxxx;&xxxx;Xx. xxxx. L 353, 31.12.2008, x.&xxxx;1.

(2)&xxxx;&xxxx;Xxxxxxxx Xxxx 67/548/EHS xx xxx 27. xxxxxx 1967 x xxxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx týkajících xx xxxxxxxxxxx, xxxxxx x označování xxxxxxxxxxxx xxxxx (Xx. věst. 196, 16.8.1967, s. 1).

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Rady (ES) x.&xxxx;1907/2006 xx xxx 18. xxxxxxxx 2006 x registraci, hodnocení, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx xxxxxxxx 1999/45/XX a x xxxxxxx xxxxxxxx Xxxx (XXX) x.&xxxx;793/93, xxxxxxxx Xxxxxx (XX) x.&xxxx;1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Xxxxxx 91/155/XXX, 93/67/EHS, 93/105/XX x 2000/21/XXXx. věst. X&xxxx;396, 30.12.2006, x.&xxxx;1.


PŘÍLOHA

Část 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 se xxxx xxxxx:

1)

Xxxxxxx 3.1 xx mění xxxxx:

x)

Xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X x&xxxx;613-149-00-7 xx xxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxx:

Xxxxxxxx číslo

Mezinárodní xxxxxxxxxxxx xxxxxxxxxx látek

Číslo XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx

Xxxx.

Xxxx xxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx o nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

Xxxx doplň. xxxxxxxxxxxx xxx o nebezpečnosti

007-004-00-1

kyselina dusičná … %

231-714-2

7697-37-2

Ox. Xxx. 2

Skin Xxxx. 1&xxxx;X

X272

X314

XXX03

XXX05

Xxx

X272

X314

XXX071

Xxxx Xxxx. 1&xxxx;X; X314: X ≥&xxxx;20 %

Xxxx Corr. 1X; X314: 5 % ≤ C &xx;&xxxx;20 %

Xx. Liq. 2; X272: C ≥&xxxx;99 %

Xx. Xxx. 3; X272: 99 % &xx; C ≥&xxxx;65 %

X

015-003-00-2

xxxxxx xxxxxxxx; xxxxxxxxxx xxxxxxxx

215-142-0

1305-99-3

Xxxxx-xxxxx. 1

Acute Tox. 2

Xxxxx Tox. 3

Xxxxx Xxx. 1

Eye Dam. 1

Xxxxxxx Xxxxx 1

X260

X300

X311

X330

X318

X400

XXX02

XXX06

XXX05

XXX09

Xxx

X260

X300

X311

X330

X318

X400

XXX029

XXX032

X&xxxx;= 100

031-001-00-4

xxxxxxx xxxxx

215-114-8

1303-00-0

Xxxx. 1X

Xxxx. 1X

XXXX RE 1

X360X

X350

X372 (xxxxxxx x&xxxx;xxxxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X350

X372 (xxxxxxx a krvetvorný xxxxxx)

050-008-00-3

xxxxxxxxxxxxxxxx xxxxxxxxxx, x&xxxx;xxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx x&xxxx;xxxx příloze

Repr. 1X

Xxxxx Xxx. 3

Xxxxx Xxx. 4*

XXXX RE 1

Skin Xxxxx. 2

Eye Xxxxx. 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X360XX

X301

X312

X372**

X315

X319

X400

X410

XXX08

XXX06

XXX09

Xxx

X360XX

X301

X312

X372**

X315

X319

X410

*

XXXX XX 1; X372: X ≥&xxxx;1 %

STOT RE 2; X373: 0,25 % ≤ X &xx;&xxxx;1 %

Xxxx Xxxxx. 2; H315:C ≥ 1 %

Xxx Xxxxx. 2; X319:X ≥ 1 %

X&xxxx;= 10

X

1

603-102-00-9

1,2-xxxxxxxxxx

203-438-2

106-88-7

Xxxx. Xxx. 2

Xxxx. 2

Xxxxx Tox. 4*

Xxxxx Xxx. 4*

Xxxxx Xxx. 4*

XXXX SE 3

Skin Xxxxx. 2

Xxx Xxxxx. 2

X225

X351

X302

X312

X332

X335

X315

X319

XXX02

XXX08

XXX07

Xxx

X225

X351

X302

X312

X332

X335

X315

X319

603-197-00-7

xxxxxxxxxxx (XXX); 1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-3-(1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxx-3-xx

403-640-2

107534-96-3

Xxxx. 2

Xxxxx Xxx. 4

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x***

X302

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x***

X302

X410

X&xxxx;= 1

X&xxxx;= 10

606-054-00-7

isoxaflutol (XXX); 5-xxxxxxxxxxx-1,2-xxxxxx-4-xx-α,α,α-xxxxxxxx-2-xxxxx-x-xxxxxxxxxx

141112-29-0

Xxxx. 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X361x***

X400

X410

XXX08

XXX09

Xxx

X361x***

X410

X&xxxx;= 10

X&xxxx;= 100

607-197-00-8

xxxxxxxx xxxxxxxx

203-931-2

112-05-0

Xxxx Irrit. 2

Xxx Xxxxx. 2

Xxxxxxx Xxxxxxx 3

X315

X319

X412

XXX07

Xxx

X315

X319

X412

613-042-00-5

xxxxxxxx (ISO); 1-[2-allyloxy-2-(2,4-dichlorfenyl)ethyl]-1H-imidazol

252-615-0

35554-44-0

Carc. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 4

Eye Xxx. 1

Xxxxxxx Chronic 1

X351

X301

X332

X318

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X351

X301

X332

X318

X410

X&xxxx;= 10

613-057-00-7

xxxxxxxxx (ISO); 4-xxxxxxxxxxxx-2,6-xxxxxxxxxxxxxxxx

216-474-9

1593-77-7

Xxxx. 2

XXXX XX 2

Skin Xxxx. 1C

Skin Xxxx. 1&xxxx;X

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X361x

X373 (xxxxx)

X314

X317

X400

X410

XXX08

XXX05

XXX07

XXX09

Xxx

X361x

X373 (xxxxx)

X314

X317

X410

XXX071

X&xxxx;= 1

X&xxxx;= 1

613-133-00-X

etridiazol (XXX); 5-ethoxy-3-trichlormethyl-1,2,4-thiadiazol

219-991-8

2593-15-9

Carc. 2

Xxxxx Xxx. 4

Xxxx Sens. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X351

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X302

X317

X410

X&xxxx;= 1

X&xxxx;= 1

613-149-00-7

xxxxxxxxx (XXX); 2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx

405-700-3

96489-71-3

Xxxxx Xxx. 3

Xxxxx Tox. 3

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X331

X301

X400

X410

XXX06

XXX09

Xxx

X331

X301

X410

X&xxxx;= 1&xxxx;000

X&xxxx;= 1&xxxx;000

x)

Xxxxxxxxxxx xxxxxxx xx xxxxxxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxxxxxxx xxxxxxx stanovených v tabulce 3.1:

Xxxxxxxx číslo

Mezinárodní identifikace xxxxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, xxxxxxxxxxxxx xxxxxxx

Xxxx.

Xxxx xxxx x&xxxx;xxxxxxxxx nebezpečnosti

Kódy standardních xxx x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx a signálních xxxx

Xxxx xxxxxxxxxxxx xxx o nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

019-003-00-3

xxxxxx-(X,X)-xxxx-2,4-xxxxxxx

246-376-1

24634-61-5

Xxx Xxxxx. 2

H319

GSH07

Wng

H319

604-092-00-9

fenol, xxxxxxx-, rozvětvený [1];

fenol, 2-xxxxxxx-, xxxxxxxxxx;

xxxxx, 3-xxxxxxx-, xxxxxxxxxx;

xxxxx, 4-dodecyl-, xxxxxxxxxx;

xxxxx, (xxxxxxxxxxxxx)xxxxxxxx&xxxx;[2]

310-154-3 [1]

121158-58-5 [1]

74499-35-7 [2]

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X314

X400

X410

XXX05

XXX09

Xxx

X314

X410

X&xxxx;= 10

M = 10

606-148-00-8

xxxxxx (XXX);

2-xxxxxx-5-(xxxx-1-xx-2-xx)xxxxxxxx-2-xx-1-xx; [1]

D-karvon; (5X)-2-xxxxxx-5-(xxxx-1-xx-2-xx)xxxxxxxx-2-xx-1-xx; [2]

X-xxxxxx; (5X)-2-xxxxxx-5-(xxxx-1-xx-2-xx)xxxxxxxx-2-xx-1-xx [3]

202-759-5 [1]

218-827-2 [2]

229-352-5 [3]

99-49-0 [1]

2244-16-8 [2]

6485-40-1 [3]

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317

606-149-00-3

xxxxxxxxxx (XXX); 2-{2-xxxxx-4-(xxxxxxxxxxxxxx)-3-[(2,2,2-xxxxxxxxxxxxxx)xxxxxx]xxxxxxx}xxxxxxxxxx-1,3-xxxx

335104-84-2

Xxxx. 2

STOT RE 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X361x

X373 (oči, xxxxxxx, xxxxx)

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx, xxxxx)

X317

X410

X&xxxx;= 100

X&xxxx;= 10

607-707-00-9

fenoxaprop-P-ethyl (XXX); ethyl-(2R)-2-{4-[(6-chlor-1,3-benzoxazol-2-yl)oxy]fenoxy}propanoát

71283-80-2

STOT RE 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X373 (xxxxxxx)

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373 (xxxxxxx)

X317

X410

X&xxxx;= 1

X&xxxx;= 1

607-708-00-4

xxxxxxxx xxxxxxxx

204-677-5

124-07-2

Xxxx Xxxx. 1C

Aquatic Xxxxxxx 3

X314

X412

XXX05

Xxx

X314

X412

607-709-00-X

xxxxxxxx kyselina

206-376-4

334-48-5

Skin Xxxxx. 2

Xxx Xxxxx. 2

Xxxxxxx Xxxxxxx 3

X315

X319

X412

XXX07

Xxx

X315

X319

X412

607-710-00-5

1,2-xxxxxxxxxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx a lineární

271-093-5

68515-50-4

Repr. 1X

X360XX

XXX08

Xxx

X360XX

607-711-00-0

xxxxxxxxxxxxx (ISO); (5x,8x)-3-(2,5-xxxxxxxxxxxxx)-8-xxxxxxx-2-xxx-1-xxxxxxxx[4,5]xxx-3-xx-4-xx-xxxxxxxxxxxxx

203313-25-1

Xxxx. 2

XXXX SE 3

Xxx Xxxxx. 2

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X361xx

X335

X319

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X361xx

X335

X319

X317

X410

X&xxxx;= 1

X&xxxx;= 1

607-712-00-6

xxxxxxxx-xxxxxx; 4-xxxxxxxxxxxx-2,6-xxxxxxxxxxxxxxxx-4-xxx-xxxxxx

250-778-2

31717-87-0

Xxxx. 2

XXXX XX 2

Skin Xxxx. 1X

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Xxxxxxx 1

H361d

H373 (xxxxx)

X314

X317

X410

XXX08

XXX05

XXX07

XXX09

Xxx

X361x

X373 (xxxxx)

X314

X317

X410

XXX071

X&xxxx;= 1

607-713-00-1

xxxxxxxxxxxx (XXX); xxxx-xxxxx-4-[({(X)-[(1,3-xxxxxxxx-5-xxxxxx-1X-xxxxxxx-4-xx)xxxxxxxx]xxxxx}xxx)xxxxxx]xxxxxxx

134098-61-6

Xxxxx Xxx. 3

Acute Xxx. 2

Xxxx Sens. 1X

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X301

X330

X317

X400

X410

XXX06 GHS09

Dgr

H301

H330

H317

H410

M = 100

X&xxxx;= 1&xxxx;000

607-714-00-7

xxxxxxxxxxxxxx-xxxxxx; methyl-2-({[4-(dimethylamino)-6-(2,2,2-trifluorethoxy)-1,3,5-triazin-2-yl]karbamoyl}sulfamoyl)-3-methylbenzoát

126535-15-7

Carc. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 100

X&xxxx;= 10

607-715-00-2

xxxxxxxxx (XXX); isopropyl-2-(4-methoxybifenyl-3-yl)hydrazinkarboxylát

442-820-5

149877-41-8

STOT XX 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H373

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H373

H317

H410

M = 1

X&xxxx;= 1

613-319-00-0

xxxxxxxx

206-019-2

288-32-4

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Corr. 1X

X360X

X302

X314

XXX08

XXX07

XXX05

Xxx

X360X

X302

X314

613-320-00-6

xxxxxxx (XXX); 3-xxxxxxxxxx-6,7-xxxxxxx-1X-xxxxxxxxxx[x]xxxxxxxxx-2,4(3X,5X)-xxxx

218-499-0

2164-08-1

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X&xxxx;= 10

X&xxxx;= 10

616-213-00-2

xxxxxxxxxxxxx (XXX); 2-(4-xxxxxxxxxx)-X-{2-[3-xxxxxxx-4-(xxxx-2-xx-1-xxxxx)xxxxx]xxxxx}-2-(xxxx-2-xx-1-xxxxx)xxxxxxxx

374726-62-2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X&xxxx;= 1

X&xxxx;= 1

616-214-00-8

xxxxxxxxx (XXX); X-(2,6-xxxxxxx-3-xxxxxxxxxxx)-5,7-xxxxxxxxx[1,2,4]xxxxxxxx[1,5-x]xxxxxxxxx-2-xxxxxxxxxx

139528-85-1

Xxxx. 2

STOT XX 2

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X351

X373 (xxx, xxxxxxx)

X400

X410

XXX08

XXX09

Xxx

X351

X373 (oči, xxxxxxx)

X410

X&xxxx;= 1&xxxx;000

X&xxxx;= 100

616-215-00-3

xxxxxxxxxxxx-X (XXX); 2-xxxxx-X-(2,4-xxxxxxxx-3-xxxxxxx)-X-[(2X)-1-xxxxxxxxxxxxx-2-xx]xxxxxxxx

163515-14-8

Xxxxx Tox. 4

Skin Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X302

X317

X400

X410

XXX07

XXX09

Xxx

X302

X317

X410

X&xxxx;= 10

X&xxxx;= 10

616-216-00-9

xxxxxxxxxx (XXX); X-(xxxxxxxxxxx)-4-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

158062-67-0

Xxxxx Xxx. 4

X302

XXX07

Xxx

X302

616-217-00-4

xxxxxxxxxxx (XXX); [xxxxxx(xxx){1-[6-(xxxxxxxxxxxxxx)-3-xxxxxxx]xxxxx}-λ6-xxxxxxxxxxxx]xxxxxxxx

946578-00-3

Xxxxx Xxx. 4

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

M = 1

X&xxxx;= 1

2)

Xxxxxxx 3.2 xx xxxx xxxxx:

x)

Xxxxxxx odpovídající xxxxxxxxx xxxxxx 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X x&xxxx;613-149-00-7 se xxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxxxx xxxxxx

Xxxxxxxx k přípravkům

007-004-00-1

kyselina xxxxxxx&xxxx;…&xxxx;%

231-714-2

7697-37-2

X; X8

X; X35

X; X

X: 8-35

S: (1/2-)26-28- 36/37/39-45-63

X; X8: X ≥&xxxx;65 %

X; X35: X ≥&xxxx;20 %

C; X34: 5 % ≤ X &xx;&xxxx;20 %

X

015-003-00-2

xxxxxx xxxxxxxx; trikalcium xxxxxxxx

215-142-0

1305-99-3

X; X15/29

X+; X26/28

Xx; X21

X32

Xx; R38-41

N; X50

X; X+; X

X: 15/29-21-26/28-32-38-41-50

S:(1/2-)26-28-30-36/37/39-43-45-60-61

N; X50: X ≥ 0,25 %

031-001-00-4

xxxxxxx xxxxx

215-114-8

1303-00-0

Xxxx. Xxx. 2; X60

Xxxx. Cat. 2; X45

X; R48/23

T

R: 45-48/23-60

X: 45-53

X

050-008-00-3

xxxxxxxxxxxxxxxx sloučeniny, x&xxxx;xxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx jinde v této xxxxxxx

Xxxx. Xxx. 2; X60-61

X; X25-48/23/25

Xx; X21

Xx; X36/38

X; R50-53

T; N

R: 21-25-36/38-48/23/25-50/53-60-61

X: 45-53-60-61

X; R25: X ≥&xxxx;2,5 %

Xx; X22: 0,25 % ≤ X &xx;&xxxx;2,5 %

Xx: X21: X ≥&xxxx;1 %

X; X48/23/25: X ≥&xxxx;1 %

Xx; X48/20/22: 0,25 % ≤ C < 1 %

Xx; X36/38: X ≥&xxxx;1 %

X; X50-53: X ≥ 2,5 %

X; X51-53: 0,25 % ≤ C &xx;&xxxx;2,5 %

X52-53: 0,025 % ≤ X &xx;&xxxx;0,25 %

X

1

603-102-00-9

1,2-xxxxxxxxxx

203-438-2

106-88-7

X; X11

Xxxx. Cat. 3; X40

Xx; X20/21/22

Xx; X36/37/38

X; Xn

R: 11-20/21/22-36/37/38-40-

X: (2-)9-16-29-36/37-46

603-197-00-7

xxxxxxxxxxx (XXX); 1-(4-chlorfenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol

403-640-2

107534-96-3

Repr. Xxx. 3; X63

Xx; X22

X; X50-53

Xx; X

X: 22-50/53-63

X: (2-)22-36/37-60-61

X; X50-53: X ≥ 25 %

X; X51-53: 2,5 % ≤ C &xx;&xxxx;25 %

X52-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

606-054-00-7

xxxxxxxxxxx (XXX); 5-cyklopropyl-1,2-oxazol-4-yl-α, α,α-xxxxxxxx-2-xxxxx-x-xxxxxxxxxx

141112-29-0

Xxxx. Cat. 3; X63

X; R50-53

Xn; N

R: 50/53-63

X: (2-)36/37-60-61

X; X50-53: X ≥&xxxx;2,5 %

N; X51-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

X52-53: 0,025 % ≤ X < 0,25 %

607-197-00-8

xxxxxxxx xxxxxxxx

203-931-2

112-05-0

Xx; X36/38

X; X51-53

Xx; N

R: 36/38-51/53

X: (2-)46-61

613-042-00-5

xxxxxxxx (ISO); 1-[2-xxxxxxxx-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx

252-615-0

35554-44-0

Xxxx. Xxx. 3; X40

Xx; X20/22

Xx; R41

N; X51-53

Xx; X

X: 20/22-40-41-51/53

X: (2-)26-36/37/39-46-61

613-057-00-7

xxxxxxxxx (XXX); 4-cyklododecyl-2,6-dimethylmorfolin

216-474-9

1593-77-7

Repr. Xxx. 3; X63

X; X34

X43

X; X50-53

X; X

X: 34-43-50/53-63

X: (1/2-)26-28-36/37/39-45-60-61

X; R34: X ≥&xxxx;10 %

Xx; R36/37/38: 5 % ≤ X &xx;&xxxx;10 %

X; X50-53: X ≥ 25 %

X; R51-53: 2,5 % ≤ C &xx;&xxxx;25 %

R52-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

613-133-00-X

xxxxxxxxxx (XXX); 5-xxxxxx-3-xxxxxxxxxxxxxx-1,2,4-xxxxxxxxxx

219-991-8

2593-15-9

Xxxx. Xxx. 3; X40

Xx; R22

R43

N; X50-53

Xx; X

X: 22-40-43-50/53

X: (2-)36/37-46-60-61

X; X50-53: X ≥ 25 %

X; X51-53: 2,5 % ≤ C &xx;&xxxx;25 %

X52-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

613-149-00-7

pyridaben (XXX); 2-xxxx-xxxxx-5-[(4-xxxx-xxxxxxxxxxx)xxxxxxxx]-4-xxxxxxxxxxxxxx-3(2X)-xx

405-700-3

96489-71-3

X; X23/25

X; X50-53

X; X

X: 23/25-50/53

X: (1/2-)36/37-45-60-61

N; X50-53: C ≥&xxxx;0,025 %

X; X51-53: 0,0025 % ≤ X &xx;&xxxx;0,025 %

X52-53: 0,00025 % ≤ X &xx;&xxxx;0,0025 %

b)

Následující xxxxxxx xx vkládají v souladu x&xxxx;xxxxxxxxxxxx xxxxxxx stanovených x&xxxx;xxxxxxx 3.2:

Xxxxxxxx xxxxx

Xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxxxx xxxxxx

Xxxxxxxx x&xxxx;xxxxxxxxxx

019-003-00-3

xxxxxx-(X,X)-xxxx-2,4-xxxxxxx

246-376-1

24634-61-5

Xx; X36

Xx

X: 36

X: (2-)25-46

604-092-00-9

xxxxx, xxxxxxx-, rozvětvený [1];

xxxxx, 2-xxxxxxx-, xxxxxxxxxx;

xxxxx, 3-xxxxxxx-, xxxxxxxxxx;

xxxxx, 4-xxxxxxx-, xxxxxxxxxx;

xxxxx, (xxxxxxxxxxxxx)xxxxxxxx&xxxx;[2]

310-154-3 [1]-[2]

121158-58-5 [1]

74499-35-7 [2]

X; R34

N; X50-53

X; N

R: 34-50/53

X: (1/2-)26-36/37/39-45-61

X; X50-53: X ≥&xxxx;2,5 %

X; R51-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

X52-53: 0,025 % ≤ X < 0,25 %

606-148-00-8

xxxxxx (XXX);

2-xxxxxx-5-(xxxx-1-xx-2-xx)xxxxxxxx-2-xx-1-xx; [1]

D-karvon; (5X)-2-xxxxxx-5-(xxxx-1-xx-2-xx)xxxxxxxx-2-xx-1-xx; [2]

X-xxxxxx; (5R)-2-methyl-5-(prop-1-en-2-yl)cyklohex-2-en-1-on [3]

202-759-5 [1]

218-827-2 [2]

229-352-5 [3]

99-49-0 [1]

2244-16-8 [2]

6485-40-1 [3]

X43

Xx

X: 43

X: (2-)24-37

606-149-00-3

tembotrion (XXX); 2-{2-xxxxx-4-(xxxxxxxxxxxxxx)-3-[(2,2,2-xxxxxxxxxxxxxx)xxxxxx]xxxxxxx}xxxxxxxxxx-1,3-xxxx

335104-84-2

Xxxx. Cat. 3; X63

Xx; X48/22

X43

X; R50-53

Xn; X

X: 43-48/22-50/53-63

X: (2-)36/37-46-60-61

X; X50-53: X ≥&xxxx;0,25 %

X; X51-53: 0,025 % ≤ X &xx;&xxxx;0,25 %

X52-53: 0,0025 % ≤ X &xx;&xxxx;0,025 %

607-707-00-9

xxxxxxxxxx-X-xxxxx (XXX); xxxxx-(2X)-2-{4-[(6-xxxxx-1,3-xxxxxxxxxx-2-xx)xxx]xxxxxx}xxxxxxxxx

71283-80-2

Xx; X48/22

X43

X; R50-53

Xn; X

X: 43-48/22-50/53

S: (2-)24-37-46-60-61

N; X50-53: X ≥&xxxx;25 %

X; X51-53: 2,5 % ≤ X &xx;&xxxx;25 %

X52-53: 0,25 % ≤ C &xx;&xxxx;2,5 %

607-708-00-4

xxxxxxxx xxxxxxxx

204-677-5

124-07-2

X; X34

X; R51-53

C; X

X: 34-51/53

X: (1/2-)26-36/37/39-45-61

607-709-00-X

dekanová xxxxxxxx

206-376-4

334-48-5

Xx; X36/38

X; X51-53

Xx; N

R: 36/38-51/53

X: (2-)25-46-61

607-710-00-5

1,2-benzendikarboxylová xxxxxxxx, xxxxxxxxxxxx, rozvětvený x&xxxx;xxxxxxxx

271-093-5

68515-50-4

Xxxx. Xxx. 2; X60-61

X

X: 60-61

X: 53-45

607-711-00-0

spirotetramat (ISO); (5x,8x)-3-(2,5-xxxxxxxxxxxxx)-8-xxxxxxx-2-xxx-1-xxxxxxxx[4,5]xxx-3-xx-4-xx-xxxxxxxxxxxxx

203313-25-1

Xxxx. Xxx. 3; X62-63

Xx; R36/37

R43

N; R50-53

Xn; X

X: 36/37-43-50/53-62-63

X: (2-)36/37-60-61

Xi; X43: X ≥ 0,1 %

X; R50-53: C ≥&xxxx;25 %

X; R51-53: 2,5 % ≤ X < 25 %

X52-53: 0,25 % ≤ X < 2,5 %

607-712-00-6

xxxxxxxx-xxxxxx; 4-xxxxxxxxxxxx-2,6-xxxxxxxxxxxxxxxx-4-xxx-xxxxxx

250-778-2

31717-87-0

Xxxx. Xxx. 3; X63

X; X34

X43

X; R51-53

C; X

X: 34-43-51/53-63

S: (1/2-)26-28-36/37/39-45-61

X; X34: X ≥ 10 %

Xx: X36/37/38: 5 % ≤ X &xx;&xxxx;10 %

607-713-00-1

fenpyroximát (XXX); xxxx-xxxxx-4-[({(X)-[(1,3-xxxxxxxx-5-xxxxxx-1X-xxxxxxx-4-xx)xxxxxxxx]xxxxx}xxx)xxxxxx]xxxxxxx

134098-61-6

X+; R26

Xn; X22

X43

X; X50-53

X+; N

R: 22-26-43-50/53

X: (1/2-)28-36/37-45-60-61-63

X; R50-53: X ≥&xxxx;0,25 %

N; R51-53: 0,025 % ≤ X &xx;&xxxx;0,25 %

R52-53: 0,0025 % ≤ X < 0,025 %

607-714-00-7

xxxxxxxxxxxxxx-xxxxxx; xxxxxx-2-({[4-(xxxxxxxxxxxxx)-6-(2,2,2-xxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2-xx]xxxxxxxxx}xxxxxxxxx)-3-xxxxxxxxxxxxx

126535-15-7

Xxxx. Xxx. 3; X40

X; X50-53

Xx; X

X: 40-50/53

X: (2-)36/37-60-61

N; R50-53: X ≥ 0,25 %

X; X51-53: 0,025 % ≤ X &xx;&xxxx;0,25 %

X52-53: 0,0025 % ≤ X &xx;&xxxx;0,025 %

607-715-00-2

xxxxxxxxx (XXX); xxxxxxxxx-2-(4-xxxxxxxxxxxxxx-3-xx)xxxxxxxxxxxxxxxxxx

442-820-5

149877-41-8

X43

X; X50-53

Xx; N

R: 43-50/53

X: (2-)24-37-60-61

X; X50-53: X ≥&xxxx;25 %

X; X51-53: 2,5 % ≤ X &xx;&xxxx;25 %

R52-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

613-319-00-0

xxxxxxxx

206-019-2

288-32-4

Xxxx. Xxx 2; X61

Xx; X22

X; R34

T; X

X: 22-34-61

X: 53-45

613-320-00-6

lenacil (XXX); 3-xxxxxxxxxx-6,7-xxxxxxx-1X-xxxxxxxxxx[x]xxxxxxxxx-2,4(3X,5X)-xxxx

218-499-0

2164-08-1

Xxxx. Cat. 3; X40

X; X50-53

Xx; X

X: 40-50/53

X: (2-)36/37-60-61

N; R50-53: X ≥&xxxx;2,5 %

X; X51-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

X52-53: 0,025 % ≤ X &xx;&xxxx;0,25 %

616-213-00-2

xxxxxxxxxxxxx (XXX); 2-(4-xxxxxxxxxx)-X-{2-[3-xxxxxxx-4-(xxxx-2-xx-1-xxxxx)xxxxx]xxxxx}-2-(xxxx-2-xx-1-xxxxx)xxxxxxxx

374726-62-2

X; X50-53

X

X: 50/53

S: 60-61

X; X50-53: X ≥&xxxx;25 %

X; X51-53: 2,5 % ≤ X &xx;&xxxx;25 %

X52-53: 0,25 % ≤ X &xx;&xxxx;2,5 %

616-214-00-8

metosulam (XXX); X-(2,6-xxxxxxx-3-xxxxxxxxxxx)-5,7-xxxxxxxxx[1,2,4]xxxxxxxx[1,5-x]xxxxxxxxx-2-xxxxxxxxxx

139528-85-1

Xxxx. Xxx. 3; X40

Xx; X48/22

X; X50-53

Xx; X

X: 40-48/22-50/53

X: (2-)36/37-46-60-61

X; X50-53: X ≥&xxxx;0,025 %

X; X51-53: 0,0025 % ≤ X &xx;&xxxx;0,025 %

X52/53: 0,00025 % ≤ X &xx;&xxxx;0,0025 %

616-215-00-3

dimethenamid-P (ISO); 2-xxxxx-X-(2,4-xxxxxxxx-3-xxxxxxx)-X-[(2X)-1-xxxxxxxxxxxxx-2-xx]xxxxxxxx

163515-14-8

Xx; X22

X43

X; R50-53

Xn; X

X: 22-43-50/53

S: (2-)24-37-60-61

N; X50-53: X ≥&xxxx;2,5 %

X; X51-53: 0,25 % ≤ C &xx;&xxxx;2,5 %

X52-53: 0,025 % ≤ X &xx;&xxxx;0,25 %

616-216-00-9

flonikamid (XXX); X-(xxxxxxxxxxx)-4-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

158062-67-0

Xx; R22

Xn

R: 22

X: (2-)46

616-217-00-4

xxxxxxxxxxx (XXX); [xxxxxx(xxx){1-[6-(xxxxxxxxxxxxxx)-3-xxxxxxx]xxxxx}-λ6-xxxxxxxxxxxx]xxxxxxxx

946578-00-3

Xx; X22

X; X50-53

Xx; X

X: 22-50/53

X: (2-)60-61

X; X50-53: X ≥&xxxx;25 %

X; X51-53: 2,5 % ≤ X &xx;&xxxx;25 %

X52-53: 0,25 % ≤ X &xx;&xxxx;2,5 %